Risk-adjusted algorithms in surgical audit attempt to adjust for patient case mix and complexity in order that published outcomes fairly reflect surgical performance and quality of care. Such risk-adjustment models have applied to head and neck squamous cell carcinoma (HNSCC). We test one algorithm, currently embedded in the oncology and reconstruction dataset within the Quality and Outcomes in Oral and Maxillofacial (QOMS) Audit, which is an artificial neural network, for its predictive accuracy on a surgical cohort receiving curative surgery for non-HNSCC pathology. A single centre retrospective case note audit of post operative complications between 2010 and 2020 was conducted on patients having curative surgery for non-HNSCC pathology. The observed complication rate was compared to the predicted probability of complications in order to test the performance of the complication risk-adjustment model. Of 1591 non-HNSCC patients, 58 met the inclusion criteria with a 30-day complication rate of 8/58 (13%). The artificial neural network predicted a complication rate of 20/58 (27%). Sensitivity (0.75), specificity (0.72) and overall accuracy (0.72) suggest acceptable discrimination. Hosmer-Lemershow Goodness of Fit test was good (p = 0.55) suggesting acceptable calibration though over-prediction of complication rate in the highest risk patents was observed. This external validation series suggests the algorithm can be applied to the non-HNSCC cohort, though some refinement of the algorithm is required to account for over-prediction of complications for higher-risk patients. With further analysis a robust means of risk adjusting for the non-HNSCC cohort should be possible.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bjoms.2022.01.006 | DOI Listing |
J Am Coll Cardiol
December 2024
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: The growing use of leadless pacemaker (LP) technology requires safe and effective solutions for retrieving and removing these devices over the long term.
Objectives: This study sought to evaluate retrieval and removal of an active helix-fixation LP studied in worldwide regulatory clinical trials.
Methods: Subjects enrolled in the LEADLESS II phase 1 investigational device exemption, LEADLESS Observational, or LEADLESS Japan trials with an attempted LP retrieval at least 6 weeks postimplantation were included.
Afr J Reprod Health
December 2024
Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
This study examined the effects of a combination of plan-do-check-action (PDCA) and enhanced recovery after surgery (ERAS) on patients undergoing cesarean section. One hundred and thirty patients undergoing caesarean section at the Second Affiliated Hospital of Nantong University comprised the study group. They were randomly divided into a control group (CG) and an intervention group (IG).
View Article and Find Full Text PDFViruses
November 2024
Department of Surgery, Campus Virchow Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Introduction: The development of chronic kidney disease (CKD) is a common and significant complication, contributing to morbidity after liver transplantation (LT). Cytomegalovirus (CMV) infection is common in the overall population, and relevant reinfection after LT may occur. CMV-associated kidney damage has been discussed, but the clinical significance on CKD development after LT remains unclear.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Urology Department, Hospital de Santa Maria, 1649-028 Lisbon, Portugal.
Background/objectives: Urinary tract infections (UTI) represent a highly frequent and debilitating disease. Immunoactive prophylaxis, such as the polyvalent bacterial whole-cell-based sublingual vaccine MV140, have been developed to avoid antibiotic use. However, the effectiveness of this tool in the Portuguese population is still unknown.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Vaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!